When paired with willing older adults, talking AI can administer and assess preliminary dementia tests in much the same way—and with similar effectiveness—as human specialists.

See What’s New:

Researchers have used a state-of-the-art microscope and advanced AI to track clotting risks in CAD patients. The goal is to spot blood clots before they even happen, ensuring patients are prescribed the right therapy for their specific needs. 

Why do investors equate these companies with beautiful, mythical beasts? Because startups with such dazzling attributes are—or long were—rarely seen.

Where a cautious President Biden wanted to confine American AI know-how to America, a freewheeling President Trump wants to turn it loose—at least to select friends and allies.

The FDA clearly sees significant potential in a new multi-protein blood test from Prevencio. The company's goal is to gain full approval and get the test in the hands of emergency departments all over the United States.

For some, the FDA is moving too fast in its drive to adopt generative AI agency-wide. 

Healthcare consumers considering the use of large language AI for mental healthcare are apt to shy away from the technology if they feel it might put their privacy at risk. 

See What’s New:

The FDA is getting AI-aggressive about speeding up device reviews. Its plan is to unleash generative AI on tedious and repetitive tasks.